Should alectinib or ceritinib be given as first line therapy for ALK positive non-small cell lung cancer patients instead of crizotinib?

TY - JOUR

T1 - Should alectinib or ceritinib be given as first line therapy for ALK positive non-small cell lung cancer patients instead of crizotinib?

AU - Peters, Godefridus J.

AU - Muller, Ittai B.

AU - Giovannetti, Elisa

PY - 2017/8/1

Y1 - 2017/8/1

UR - http://www.scopus.com/inward/record.url?scp=85028502472&partnerID=8YFLogxK

U2 - https://doi.org/10.21037/tcr.2017.06.54

DO - https://doi.org/10.21037/tcr.2017.06.54

M3 - Editorial

SN - 2218-676X

VL - 6

SP - S1010-S1013

JO - Translational Cancer Research

JF - Translational Cancer Research

ER -